Pramipexole dihydrochloride_104632-25-9_DataSheet_MedChemExpress

Product Name:

Pramipexole dihydrochloride CAS No.:

104632-25-9Cat. No.:

HY-17355Product Data Sheet

MWt:

284.25Formula:

C10H19Cl2N3S Purity :>98%

Solubility:Water >20 mg/mL DMSO >80

y Mechanisms:Biological Activity:

Pramipexole 2Hcl is a partial/full D2S D2L D3D4receptor agonist with a Ki of 392205and 51

Pathways:GPCR/G protein; Target:Dopamine Receptor

Pathways:Neuronal Signaling; Target:Dopamine Receptor mg/mL

Pramipexole 2Hcl is a partial/full D2S, D2L, D3, D4 receptor agonist with a Ki of 3.9, 2.2, 0.5 and 5.1

nM for D2S, D2L, D3, D4 receptor, respectively.

IC50 Value: 3.9 nM(D2S); 2.2 nM(D2L); 0.5 nM(D3); 5.1 nM(D4)

Target: Dopamine Receptor Pramipexole dihydrochloride is a dopamine receptor agonist with selectivity for the D3 receptor (Ki values are 3.9, 3.3, 0.5 and 3.9 nM for D2L, D2S, D3 and D4 receptors respectively). Pramipexole dihydrochloride exhibits negligable affinity for D1 and D5 receptors. Pramipexole has been found to have neuroprotective effects independent of its dopamine receptor agonism. It reduces

mitochondrial reactive oxygen species (ROS) production and inhibits the activation of apoptotic References:

[1]. Mierau J, Schneider FJ, Ensinger HA et al. Pramipexole binding and activation of cloned and

expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol. 1995 Jun 23;290(1):29-36.[2]. El-Mallakh RS, Penagaluri P, Kantamneni A et al. Long-term use of pramipexole in bipolar yg p ()p p p

pathways. Pramipexole displays activity in the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS)....

[]g g p p p

depression: a naturalistic retrospective chart review. Psychiatr Q. 2010 Sep;81(3):207-13.[3]. Perez-Lloret S, Rey MV, Ratti L, Rascol O. Pramipexole for the treatment of early Parkinson's

disease. Expert Rev Neurother. 2011 Jul;11(7):925-35.[4]. Hametner EM, Seppi K, Poewe W. Pramipexole extended release in Parkinson's disease. Expert

Rev Neurother. 2011 Sep;11(9):1229-34.[5]. Hametner EM, Seppi K, Poewe W. Role and clinical utility of pramipexole extended release in

the treatment of early Parkinson's disease. Clin Interv Aging. 2012;7:83-8....

Caution: Not fully tested. For research purposes only

Medchemexpress LLC

https://www.wendangku.net/doc/8d13980038.html,

18 W i l k i n s o n W a y , P r i n c e t o n , N J 08540,U S A

E m a i l : i n f o @m e d c h e m e x p r e s s .c o m W e b : w w w .m e d c h e m e x p r e s s .c o m